Peeraphatdit T, Nkomo VT, Naksuk N, et al. - Researchers conducted the study for comparing outcomes following transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in individuals with cirrhosis to inform the preferred intervention. Data on 105 consecutive patients with cirrhosis and aortic stenosis who underwent TAVR (n = 55) or SAVR (n = 50) were reviewed retrospectively between 2008 and 2016. There were two control groups: 2,680 patients with no cirrhosis undergoing TAVR and SAVR and 17 patients with cirrhosis receiving medical therapy alone. TAVR and SAVR both have acceptable and similar short-term outcomes in selected patients with cirrhosis. Long-term survival after TAVR and SAVR is independently predicted by the Model for End-Stage Liver Disease score, but not by the Society of Thoracic Surgeons score. SAVR is a preferred procedure for patients with a MELD score < 12. However, neither procedure seems superior to medical therapy in patients with MELD score ≥ 12.